Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has entered into a research collaboration with Genetic Leap, a U.S. biotech firm specializing in artificial intelligence (AI) and RNA genetic medicine. This partnership expands on a previously successful pilot and will see Genetic Leap apply its RNA-targeted AI platform to develop oligonucleotide drugs for targets specified by Lilly across high-priority therapeutic areas.
As per the agreement, Genetic Leap stands to receive up to USD 409 million in a combination of upfront payments, development milestones, clinical achievements, regulatory accomplishments, and commercial milestones. The deal also includes provisions for tiered royalties on future sales of any products that may result from the collaboration.- Flcube.com
